Tasosartan
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
|
|
| Clinical data | |
| Pregnancy category |
|
| Legal status |
|
| Identifiers | |
| CAS Registry Number | 145733-36-4  |
| ATC code | C09CA05 |
| PubChem | CID: 60919 |
| IUPHAR/BPS | 6898 |
| DrugBank | DB01349 |
| ChemSpider | 54890  |
| UNII | 48G92V856H |
| Chemical data | |
| Formula | C23H21N7O |
| Molecular mass | 411.459 g/mol |
 (what is this?) (verify) |
|
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References[edit]
- ^ Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5.
- ^ Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm 57 (13): 1231–41. PMID 10902066.
|
||||||||||||||||||||||||||||||||
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
